Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Brian I. Rini; Michael B. Atkins; Elizabeth R. Plimack; Denis Soulières; Raymond S. McDermott; Jens Bedke; Sophie Tartas; Boris Alekseev; Bohuslav Melichar; Yaroslav Shparyk; Chihiro Kondoh; Przemyslaw Langiewicz; Lori A. Wood; Hans Hammers; Cynthia G. Silber; Barbara Haber; Erin Jensen; Mei Chen; Thomas Powles

doi:10.1016/j.euo.2021.05.007

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Brian I. Rini, Michael B. Atkins, Elizabeth R. Plimack, Denis Soulières, Raymond S. McDermott, Jens Bedke, Sophie Tartas, Boris Alekseev, Bohuslav Melichar, Yaroslav Shparyk, Chihiro Kondoh, Przemyslaw Langiewicz, Lori A. Wood, Hans Hammers, Cynthia G. Silber, Barbara Haber, Erin Jensen, Mei Chen, Thomas Powles

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Original language	English
Pages (from-to)	225-234
Number of pages	10
Journal	European urology oncology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1016/j.euo.2021.05.007
Publication status	Published - Apr 1 2022
Externally published	Yes

ASJC Scopus Subject Areas

General Medicine

Access to Document

10.1016/j.euo.2021.05.007

Cite this

Rini, B. I., Atkins, M. B., Plimack, E. R., Soulières, D., McDermott, R. S., Bedke, J., Tartas, S., Alekseev, B., Melichar, B., Shparyk, Y., Kondoh, C., Langiewicz, P., Wood, L. A., Hammers, H., Silber, C. G., Haber, B., Jensen, E., Chen, M., & Powles, T. (2022). Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. European urology oncology, 5(2), 225-234. https://doi.org/10.1016/j.euo.2021.05.007

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. / Rini, Brian I.; Atkins, Michael B.; Plimack, Elizabeth R. et al.
In: European urology oncology, Vol. 5, No. 2, 01.04.2022, p. 225-234.

Research output: Contribution to journal › Article › peer-review

Rini, BI, Atkins, MB, Plimack, ER, Soulières, D, McDermott, RS, Bedke, J, Tartas, S, Alekseev, B, Melichar, B, Shparyk, Y, Kondoh, C, Langiewicz, P, Wood, LA, Hammers, H, Silber, CG, Haber, B, Jensen, E, Chen, M & Powles, T 2022, 'Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial', European urology oncology, vol. 5, no. 2, pp. 225-234. https://doi.org/10.1016/j.euo.2021.05.007

@article{6ef92617b1be46ab9d0080c67b60995f,

title = "Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial",

author = "Rini, {Brian I.} and Atkins, {Michael B.} and Plimack, {Elizabeth R.} and Denis Souli{\`e}res and McDermott, {Raymond S.} and Jens Bedke and Sophie Tartas and Boris Alekseev and Bohuslav Melichar and Yaroslav Shparyk and Chihiro Kondoh and Przemyslaw Langiewicz and Wood, {Lori A.} and Hans Hammers and Silber, {Cynthia G.} and Barbara Haber and Erin Jensen and Mei Chen and Thomas Powles",

note = "Publisher Copyright: Copyright {\textcopyright} 2021. Published by Elsevier B.V.",

year = "2022",

month = apr,

day = "1",

doi = "10.1016/j.euo.2021.05.007",

language = "English",

volume = "5",

pages = "225--234",

journal = "European urology oncology",

issn = "2588-9311",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

AU - Rini, Brian I.

AU - Atkins, Michael B.

AU - Plimack, Elizabeth R.

AU - Soulières, Denis

AU - McDermott, Raymond S.

AU - Bedke, Jens

AU - Tartas, Sophie

AU - Alekseev, Boris

AU - Melichar, Bohuslav

AU - Shparyk, Yaroslav

AU - Kondoh, Chihiro

AU - Langiewicz, Przemyslaw

AU - Wood, Lori A.

AU - Hammers, Hans

AU - Silber, Cynthia G.

AU - Haber, Barbara

AU - Jensen, Erin

AU - Chen, Mei

AU - Powles, Thomas

PY - 2022/4/1

Y1 - 2022/4/1

UR - http://www.scopus.com/inward/record.url?scp=85130001872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130001872&partnerID=8YFLogxK

U2 - 10.1016/j.euo.2021.05.007

DO - 10.1016/j.euo.2021.05.007

M3 - Article

C2 - 34244116

AN - SCOPUS:85130001872

SN - 2588-9311

VL - 5

SP - 225

EP - 234

JO - European urology oncology

JF - European urology oncology

IS - 2

ER -

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this